Middle East Genome Editing Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The MEA genome editing market covers technologies and services used to precisely modify DNA sequences in living organisms, with applications spanning gene therapy, functional genomics, agricultural biotechnology, and industrial biotechnology. The regional market was valued at approximately USD 272.8 million in 2024 and is projected to grow to roughly USD 317.1 million in 2025, with further expansion expected as regional healthcare infrastructure and research capabilities mature. The MEA segment represents a smaller but rapidly growing share of the global genome editing market, which itself is valued at over USD 10.6 billion in 2025 and forecast to surpass USD 44 billion by 2035.

• •Global genome editing market valued at approximately USD 10.6-11.5 billion in 2025, with projections ranging to USD 23.7-52.6 billion by 2030-2035 depending on methodology
• •MEA regional market estimated at roughly USD 272.8 million in 2024, growing toward approximately USD 317.1 million in 2025
• •CRISPR-Cas9 is the dominant technology platform globally, with the dedicated CRISPR market valued at approximately USD 1.54 billion in 2023 and projected to reach roughly USD 12.1 billion by 2032

Robust market expansion is fueled by substantial government-led healthcare and biotechnology investments, particularly across Gulf nations pursuing economic diversification agendas that prioritize life sciences. Rising incidence of genetic disorders and chronic diseases, combined with growing awareness of precision medicine applications, is driving demand for advanced genome editing tools. Additionally, the agricultural sector across Africa and the Middle East is increasingly exploring genome editing to improve crop resilience against drought and salinity, supporting food security objectives.

• •Government-backed biotechnology and healthcare infrastructure programs in Saudi Arabia, UAE, and other GCC states are accelerating adoption of advanced molecular biology platforms
• •Expanding pharmaceutical R&D activity and rising demand for personalized medicine therapies are increasing procurement of genome editing services and instruments
• •Agricultural biotechnology applications addressing food security through improved crop traits represent a significant emerging demand segment across African and Middle Eastern markets

The genome editing market is segmented by technology into CRISPR-Cas systems, TALEN, ZFN, meganucleases, and related platforms, with CRISPR commanding the largest and fastest-growing share. Application segmentation includes gene therapy, cell line engineering, functional genomics, diagnostics, and agricultural biotechnology, with therapeutic applications representing the highest-value segment globally. Regionally within MEA, the GCC countries lead in market activity, followed by South Africa and select Levant and North African nations with established research infrastructure.

• •CRISPR-Cas systems dominate the technology segment due to superior precision, lower cost, and ease of use compared to earlier-generation editing tools
• •Therapeutic and pharmaceutical R&D applications account for the largest revenue share, with agricultural and industrial biotechnology segments growing at accelerated rates
• •Gulf Cooperation Council markets represent the primary MEA demand center, with growing activity in South Africa, Egypt, and select other African nations as local research capacity expands

Who are the notable companies in the industry?

The Middle East genome editing market is shaped by a mix of global life science leaders and regional innovators driving CRISPR adoption and precision medicine applications. Thermo Fisher Scientific Inc. and Merck KGaA provide foundational tools and reagents for research and therapeutic development, while Lonza supports clinical-scale cell and gene therapy manufacturing. Horizon Discovery Group plc contributes proprietary gene editing cell lines and CRISPR platforms for target validation. In the regional landscape, First Genomix delivers advanced genetic diagnostics via NGS and mutation screening, enabling personalized healthcare in the UAE. G42 Healthcare leverages its Omics Centre of Excellence to offer AI-powered sequencing and population genomics services, directly supporting gene editing research and precision therapeutics. Igenomix Middle East specializes in reproductive genetics, providing whole exome sequencing and precision panels to improve outcomes in fertility and prenatal care. CureLeads, as a pharmaceutical manufacturer, focuses on developing gene-based therapeutics tailored to regional monogenic disorders such as beta-thalassemia and sickle cell anemia. Together, these players form a vertically integrated ecosystem, spanning diagnostics, research tools, therapeutic development, and clinical translation, underpinned by national genomics initiatives and growing local R&D infrastructure across the UAE and Saudi Arabia.

• •Industry features a mix of large-scale integrated life science corporations and smaller specialty biotechnology firms, with ongoing consolidation as major players acquire innovative genome editing platforms
• •Primary technology routes include CRISPR-Cas9 and its variants (Cas12, Cas13), TALENs, zinc-finger nucleases, and emerging base and prime editing systems, with CRISPR dominating current commercial activity
• •Research and manufacturing capacity is concentrated in North America, Europe, and China globally, with MEA capacity still nascent and primarily consisting of contract research organizations, distributor partnerships, and government-sponsored research institutes

What are the recent trends and outlook?

The market trajectory points toward sustained double-digit growth, with falling costs of gene editing tools and expanding clinical trial activity for CRISPR-based therapies driving broader accessibility. Prime editing and base editing technologies are advancing toward commercial maturity, promising higher precision and fewer off-target effects. In the MEA specifically, rising domestic R&D investment, increasing local biomanufacturing ambitions, and growing participation in international collaborative research programs position the region for above-average market growth through 2035.

• •Next-generation editing technologies including base editing and prime editing are advancing toward clinical and commercial deployment, expected to expand addressable applications beyond current CRISPR limitations
• •The genome editing services segment, valued at approximately USD 2.1 billion in 2025, is growing steadily as contract research organizations expand capabilities to serve pharmaceutical and biotechnology clients globally
• •MEA market is positioned for accelerated growth as regional governments increase life sciences funding, local talent development programs expand, and international technology partnerships bring advanced capabilities to the region